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Abstract
Background: New sequencing technologies have enabled the identification of mutations in Ten-eleven-translocation 2
(TET2), an enzyme that catalyzes the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5-hmC) in myeloid
neoplasms. We have recently identified reduced TET2 mRNA expression in myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML), which is associated with a poor overall survival in MDS. We herein aimed to investigate TET2
mutations and their impact on TET2 expression in a cohort of patients with myeloid neoplasms, including MDS and
AML patients.
Findings: TET2 mutations were observed in 8 out of 19 patients (42 %) with myeloid neoplasms. The TET2 expression
profile was similar between in wild type and in TET2 mutated patients.
Conclusion: Our results suggest that TET2 expression is reduced in MDS/AML patients, independently of mutational
status.
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Findings
Introduction
New sequencing technologies have enabled the identifi-
cation of several mutations in epigenetic regulator genes,
such as Ten-eleven-translocation 2 (TET2), which en-
codes an enzyme that catalyzes the conversion of 5-
methylcytosine into 5-hydroxymethylcytosine (5-hmC).
Mutations in the coding regions of TET2 lead to loss of
TET2 protein function, reduce 5-hmc levels and cause a
significant shift towards monocyte/granulocyte differen-
tiation in detriment of erythroid/lymphoid differenti-
ation [1, 2]. TET2 mutations confer a worse prognosis in
myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) [3, 4]. We have recently reported that
TET2 mRNA expression is downregulated in MDS and
AML, and predicts poor overall survival in MDS patients
[5]. However, the correlation between the presence of
TET2 mutations and TET2 transcript levels has rarely
been addressed [4, 6]. We, herein, expanded our previ-
ous observations and aimed to investigate TET2 muta-
tional status and the impact of this mutational status on
TET2 expression in a cohort of MDS and AML patients.
For this purpose, TET2 mutation analysis and TET2 gene
expression were tested by Sanger sequencing and quan-
titative PCR, respectively, in bone marrow samples from
healthy donors and myeloid neoplasm patients.
Materials and methods
Patients’ characteristics
Bone marrow samples were obtained from a total of 22
healthy donors, and 19 patients with myeloid neoplasms
(MDS = 10 and AML = 9) followed at the outpatient
clinics of the University of Campinas, who had also been
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included in a previous study [5]. The present study was
approved by the Institutional and National Review Board
in accordance with the Helsinki Declaration. Written in-
formed consent was obtained from all patients who partic-
ipated in this study. Patients were diagnosed according to
the 2008 Word Health Organization criteria [7]. Patients’
characteristics are described in Table 1.
Polymerase chain reaction (PCR) and DNA sequencing
The screening of TET2 mutations was performed on
coding exons 3, 4, 5, 6, 7, 8, 9, 10 and 11 (GenBank ref-
erence NM_0175628.4). Primer sequences and PCR
conditions were previously described [8]. Amplicons were
sequenced with an ABI 3500 Genetic Analyzer (Life Tech-
nologies, Carlsbad, CA, USA) using the Big Dye terminator
V1.1 cycle sequencing kit and analyzed using CLC Main
Workblench v.7.6.2 software (Qiagen, Aarhus, Denmark).
All alterations found were searched in SNP (dbSNP; http://
www.ncbi.nlm.nih.gov/projects/SNP), Ensembl Genome
Browser databases (http://asia.ensembl.org/index.html),
and in the Catalogue of Somatic Mutations in Cancer
(COSMIC; http://cancer.sanger.ac.uk/cosmic).
Quantitative PCR (qPCR)
Total RNA was extracted from cells using the TRIzol
reagent (Life Technologies, Carlsbad, CA, USA). The
reverse transcription reaction was performed using
RevertAid™ First Strand cDNA Synthesis Kit (MBI
Fermentas, St. Leon-Rot, Germany). TET2 mRNA level
was detected by Maxima Sybr green qPCR master mix
(MBI Fermentas, St. Leon-Rot, Germany) in the ABI 7500
Sequence Detection System (Life Technologies) using
specific primers: forward 5′- ACGCAAGCCAGGCTAA
ACA -3′, reverse 5′- GCTGGGACTGCTGCATGA -3′;
HPRT1 (hypoxanthine phosphoribosyltransferase 1) was
used as the endogenous control: forward 5′-GAACGT
CTTGCTCGAGATGTGA-3′, reverse 5′-TCCAGCAGG
TCAGCAAAGAAT-3′. The relative quantification value
was calculated using the equation, 2-ΔΔCT [9]. A negative
‘No Template Control’ was included for each primer pair.
The dissociation protocol was performed at the end of
each run to check for non-specific amplifications. Three
replicas were run on the same plate for each sample.
Statistical analyses
Statistical analyses were performed using GraphPad Instat
5 (GraphPad Software, Inc., San. Diego, CA, USA). For
comparisons, Mann-Whitney test was used for measured
factors with two levels. A p value <0.05 was considered as
statistically significant.
Results and discussion
We analyzed the mutation status of TET2 exons and the
impact of this status on TET2 expression in bone marrow
cells from myeloid neoplasm patients. In total, 17 TET2
variants were detected. After excluding confirmed SNPs
(P29R [rs12498609], V218M [rs6843141], P363L [rs17253
672], G355D [rs61744960], H1778R [rs62621450], I1762V
[rs2454206] and L1721W [rs34402524]), TET2 mutations
were observed in 8/19 (42 %) patients with myeloid
neoplasms [4/10 (40 %) MDS and 4/9 (44 %) AML], in-
cluding six missense (E709K, Y867H, H924R, S1109P,
P1723S and H1868L) and three stop codon (E1073X,
S1516X and S1518X) mutations (Fig. 1). A total of nine
TET2 mutations were found in exon 3 (n = 5) or exon 11
(n = 3) in eight patients; one patient had two mutations.
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Abbreviations: MDS myelodysplastic syndromes, WHO World Health Organization,
RA refractory anemia, RARS refractory anemia with ringed sideroblasts, del(5q)
MDS with isolated del(5q), RCMD refractory cytopenia with multilineage dysplasia,
RAEB-1 refractory anemia with excess blast-1, BM bone marrow, IPSS-R Revised
International Prognostic Scoring System, AML acute myeloid leukemia
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Fig. 1 TET2 mutations identified in myelodysplastic syndromes and acute myeloid leukemia patients. In a cohort of 19 patients, nine TET2 mutations were
identified in eight patients. Genomic sequencing of protein-coding regions revealed missense (black arrows), and stop codon (red arrows) mutations in
TET2; Sanger sequencing analysis is illustrated in the figure. TET2 protein primary structure indicating the domains and specific known conserved motifs are
shown: cysteine-rich region (C-rich), double strand beta helix (DSBH). The aminoacid position is indicated
Fig. 2 TET2 expression, according to TET2 mutational status, in myelodysplastic syndromes and acute myeloid leukemia patients. a qPCR analysis
of Ten-eleven-translocation 2 (TET2) mRNA levels in total bone marrow cells from healthy donors and from patients with the diagnosis of myelodysplastic
syndromes (MDS)/acute myeloid leukemia (AML). TET2 expression in patients stratified according to TET2 mutational status for the entire cohort of MDS/
AML patients (b), for patients with MDS (c) or AML diagnosis (d). The “y” axis represents the relative TET2 mRNA expression. The numbers of subjects
studied and the p values (Mann-Whitney) are indicated in the graph. Abbreviations: WT wild type, MUT mutated
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Four TET2 mutations (E1073X, S1109P, S1518X and
H1868L) found in our study had not been previously de-
scribed in the COSMIC database. Among the six missense
mutations, three mutations presented a high probably of
damage to protein function, according to Polyphen2 ana-
lysis. The PolyPhen2 scores for predicted damage of TET2
Y867H, S1109P and H1868L mutations were 0.999, 0.995
and 1, respectively (http://genetics.bwh.harvard.edu/pph2/).
TET2 mutations in exons have been implicated in protein
loss-of-function and myeloid neoplasm mechanism of dis-
ease [1, 2], which supports our focus on sequencing TET2
coding regions only. The relevance of mutations in the
TET2 promoter region has not been explored yet in mye-
loid neoplasms.
TET2 expression was reduced in MDS/AML patients
(median 0.8 [minimum 0.01- maximum 6.41]), compared
with healthy donors (2.72 [0.43–31.49]); p <0.005 (Fig. 2a).
The standard deviation of TET2 expression for the healthy
donors was high in our cohort of patients, which is in
agreement with reports from other authors [4, 10]. TET2
expression was similar in TET2 wild type (0.8 [0.01–3.79])
and in mutated patients (1.82 [0.14–6.41]), for the entire
cohort, and among patients with MDS and AML only, all
p >0.05 (Fig. 2b–d). These findings are in agreement with
Jankowska and colleagues [4] and Coutinho and col-
leagues [6], who reported TET2 downregulation in 16 pa-
tients with MDS/myeloproliferative neoplasms and in 12
patients with pediatric MDS, respectively, regardless of
TET2 mutational status. Reduced TET2 levels in MDS
patients have also been previously reported by our group
[5], Li and collaborators [10], and Zhang and collaborators
[11]. However, the TET2 mutation was not evaluated in
these studies.
Somatic mutations in TET2 have been described in
healthy elderly individuals with clonal hematopoiesis
and have been associated with alterations in DNA
methylation [12]. TET2 mutations have been indicated
as early events in clonal evolution and potently lead to
the development of preleukemic hematopoietic stem
cells [13, 14]. For this reason, growing attention has
been given to the hypothesis that TET2 is a gate keeper
in hematological malignancies. The occurrence of TET2
mutations may indirectly lead to the disruption of other
important genes by inducing epigenetic changes, as
recently described for JAK2 [15]. TET2 mutations alter
the transcriptional consequences of JAK2 V617F in a
cell-intrinsic manner and prevent JAK2 V617F from
up-regulating a proliferative program [15]. In addition,
Kameda et al. [16] and Rasmussen and collaborators
[17] demonstrated, using mouse models, that the loss
of Tet2 contributes towards the progression of myeloid
neoplasms. Thus, reduced TET2 function, due to loss-of-
function mutations, reduced mRNA expression due to
epigenetic silencing or not yet elucidated mechanisms
may have a great contribution to the malignant phenotype
of hematological cancers.
Taken together, our findings suggest that decreased
TET2 expression is observed in myeloid neoplasms and
does not correlate with TET2 mutation status. Other mo-
lecular mechanisms, including mutations of additional
genes and/or epigenetic regulation may affect TET2 ex-
pression in myeloid neoplasms [18]. TET2 mRNA expres-
sion levels, in addition to TET2 mutation status, may also
play a role in myeloid neoplasm physiopathology. Future
studies to further investigate the mechanisms that lead to
reduced TET2 expression in hematological malignancies
will be of importance.
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